Literature DB >> 16056144

Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura.

Simon Akerman1, Peter J Goadsby.   

Abstract

Cortical spreading depression is thought to be the pathophysiological correlate of the neurological symptoms in migraine with aura. Topiramate is an anti-epileptic drug that is also used as a migraine preventive. Ion homeostasis and excitatory amino acid efflux are major components of cortical spreading depression; so given the broad range of actions of topiramate, we examined its effect on cortical spreading depression. Cortical spreading depression was elicited by a needle stick in the cortex in surgically prepared rats and cats; laser Doppler probes were used to measure the cerebral blood flow and a recording electrode was used to measure electrical nerve cell activity. Topiramate at 30 mg kg(-1) was able to inhibit regional cerebral blood flow changes and cortical depolarization and spreading depression in all rats, and in 8 of 13 cats. We conclude that topiramate may act on mechanisms involved in the initiation and propagation of spreading depression, and that these mechanisms may be similar to those involved in the therapeutic role.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16056144     DOI: 10.1097/01.wnr.0000175250.33159.a9

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  31 in total

1.  Intranasally administered IGF-1 inhibits spreading depression in vivo.

Authors:  Yelena Y Grinberg; Lois A Zitzow; Richard P Kraig
Journal:  Brain Res       Date:  2017-09-23       Impact factor: 3.252

Review 2.  Pharmacological targeting of spreading depression in migraine.

Authors:  Katharina Eikermann-Haerter; Anil Can; Cenk Ayata
Journal:  Expert Rev Neurother       Date:  2012-03       Impact factor: 4.618

3.  Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache.

Authors:  A Laine Green; Pengfei Gu; Milena De Felice; David Dodick; Michael H Ossipov; Frank Porreca
Journal:  Cephalalgia       Date:  2013-12-11       Impact factor: 6.292

4.  Nociceptive blink reflex habituation biofeedback in migraine.

Authors:  M de Tommaso; M Delussi
Journal:  Funct Neurol       Date:  2017 Jul/Sep

Review 5.  Glutamate and Its Receptors as Therapeutic Targets for Migraine.

Authors:  Jan Hoffmann; Andrew Charles
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

6.  Systematic review of the pharmacological agents that have been tested against spreading depolarizations.

Authors:  Anna Klass; Renan Sánchez-Porras; Edgar Santos
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-20       Impact factor: 6.200

Review 7.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

Review 8.  Cortical spreading depression and migraine.

Authors:  Andrew C Charles; Serapio M Baca
Journal:  Nat Rev Neurol       Date:  2013-09-17       Impact factor: 42.937

9.  Episodic Aphasia Associated With Cortical Spreading Depression After Subdural Hemorrhage Evacuation.

Authors:  Nirav H Shah; David Adams
Journal:  Neurohospitalist       Date:  2016-01

Review 10.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.